Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631923 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3MAP2K4PARP14 | |
| SCHEMBL3034148 | 0.84 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3USP30GPR119 | |
| SCHEMBL11988478 | 0.81 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3OPRK1PDE4D | |
| SCHEMBL14818544 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3OPRK1PDE4D | |
| SCHEMBL24223887 | 0.80 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3WDR5 | |
| SCHEMBL22471536 | 0.80 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3WDR5 | |
| SCHEMBL28730740 | 0.80 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3WDR5 | |
| SCHEMBL6491111 | 0.78 | GPR119 (0.46) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12094592 | 0.78 | GPR119 (0.46) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL16489773 | 0.78 | WDR5 (0.40) | SLC6A2SLC6A4SLC6A3GPR119CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037420-B1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2173746-B1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-3037420-A1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | Theravance Biopharma R&D IP, LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8476440-B2 | Process for preparing an intermediate to mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130079523-A1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8247559-B2 | Process for preparing an intermediate to mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110166355-A1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7932402-B2 | Process for preparing an intermediate to opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2173746-A2 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009014610-A2 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20090023934-A1 | Process for preparing an intermediate to opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023934-A1 | Process for preparing an intermediate to opioid receptor antagonists | OPRD1, OPRM1, OPRK1 | SLC6A2 1052/4885SLC6A4 967/4885SLC6A3 431/4885 |
| US-20110166355-A1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SLC6A2 1406/4885SLC6A4 1176/4885SLC6A3 664/4885 |
| US-20130079523-A1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | SLC6A2 1406/4885SLC6A4 1176/4885SLC6A3 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.